SecBot SecBot

KNSA

Kiniksa Pharmaceuticals International, plc
Nasdaq· Pharmaceutical Preparations· CIK 0001730430 Biotech & Drug Discovery
$74.55 −2.18 (−2.84%)
Oct 26 4:00 PM ET · prev $76.73
Market cap
$6.3B
Mid cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
$98.50
+32% · range $87.00–108.00
1 year
+83.6%
from $40.60 · Oct 27
30 days
−2.0%
from $76.10
52-week range
$37.01–83.17
−10% from high · low Oct 31
Avg volume 20D
596.1K
shares / day
Short interest
3.78M
≈4.8% of shares · −2.5%
Days to cover
6.4
at average volume
Insider net
-$668.5K
0 buyers · 2 sellers · since Jul 1
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3
Strongest NEUTRAL Kiniksa appointed Ross Moat as President and COO, effective immediately, with a base salary increase to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $668.5K.

  • InstitutionsMIXED

    Q2 2026: 27 added (0 new), 26 trimmed or exited.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −2.5% to 3.78M shares. 6.4 days to cover, ≈4.8% of shares.

  • TrendRANGE

    4% below its 50-day average. New closing high $83.17 on Oct 20.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED2,739,615$175.2M
STATE STREET CORPDOUBLED704,194$45.0M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED604,180$38.6M
D. E. Shaw & Co., Inc.TRIM569,756$36.4M
BNP PARIBAS FINANCIAL MARKETSTRIM437,192$28.0M
BANK OF AMERICA CORP /DE/TRIM413,411$26.4M
DEUTSCHE BANK AG\TRIM387,606$24.8M
NORTHERN TRUST CORPDOUBLED315,246$20.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +32%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 30, 2026Goldman Sachs
MAINTAIN
MAINTAINBuy
Jul 29, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Jul 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Jul 29, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Jul 29, 2026Citigroup
MAINTAIN
MAINTAINBuy
Jul 23, 2026Goldman Sachs
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$668.5K
sold · 2 insiders
DateInsiderTypeValue
Sep 3, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
SELL$369.4K
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
EXERCISE2,558 sh
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
EXERCISE3,932 sh
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
EXERCISE2,644 sh
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
AWARD3,650 sh
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
TAX W/H$438.5K
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
EXERCISE2,362 sh
Sep 1, 2026
Megna Michael R
CHIEF ACCOUNTING OFFICER
AWARD14,600 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.29$0.23–$0.33+2.6%$277.6M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
3,778,657
shares short
-2.5%
vs prior settlement
6.4
days to cover
≈4.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Earnings calendar
🔒 Fresh data, subscribers only
Oct 22, 2026 SEC
Kiniksa appointed Ross Moat as President and COO, effective immediately, with a base salary increase to $700,000 and…
8-K — Impact 2/10
Oct 22, 2026 SEC
Kiniksa Pharmaceuticals International, Plc announced it will report its Q3 2026 results on October 27, 2026.
PRESS-RELEASE — Impact 1/10
Sep 3, 2026 SEC
Officer Michael R. Megna filed a Form 144 to sell 4,600 Class A ordinary shares of Kiniksa Pharmaceuticals, with an…
144 — Impact 2/10
Sep 3, 2026 Insider
Megna Michael R sold 4,600 shares
CHIEF ACCOUNTING OFFICER @ $80.30 ($369.4K)
Sep 1, 2026 Insider
Megna Michael R acquired via exercise 2,558 shares
CHIEF ACCOUNTING OFFICER
Sep 1, 2026 Insider
Megna Michael R acquired via exercise 3,932 shares
CHIEF ACCOUNTING OFFICER
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,739,615 shares ($175.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Earnings date
🔒 Fresh data, subscribers only
Oct 22, 2026
Earnings
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference…
Sep 4, 2026
Press release
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will…
Aug 7, 2026
Press release
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate…
Jul 28, 2026
Earnings
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net…

SecBot reports

14 filings · 3 bullish · 2 bearish · 1 mixed · 8 neutral
All KNSA filing & press-release reports (14)